Several other analysts also recently weighed in on the company. StockNews.com initiated coverage on Syneos Health in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Jefferies Financial Group downgraded Syneos Health from a “buy” rating to a “hold” rating and cut their price target for the stock from $101.00 to $75.00 in a research report on Monday, April 25th. Mizuho reduced their price objective on Syneos Health from $109.00 to $94.00 and set a “buy” rating for the company in a research note on Monday, March 7th. Barclays dropped their target price on Syneos Health from $115.00 to $105.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Syneos Health in a research report on Monday, April 11th. They set a “buy” rating and a $102.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Syneos Health has a consensus rating of “Buy” and a consensus price target of $100.33.
Syneos Health stock opened at $69.77 on Wednesday. Syneos Health has a twelve month low of $66.73 and a twelve month high of $104.18. The business has a fifty day moving average of $76.85 and a two-hundred day moving average of $87.09. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.89. The firm has a market cap of $7.16 billion, a P/E ratio of 30.20 and a beta of 1.79.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Arizona State Retirement System increased its holdings in shares of Syneos Health by 0.4% in the 3rd quarter. Arizona State Retirement System now owns 28,272 shares of the company’s stock valued at $2,473,000 after acquiring an additional 107 shares during the period. Neuberger Berman Group LLC increased its stake in Syneos Health by 1.9% in the 3rd quarter. Neuberger Berman Group LLC now owns 5,750 shares of the company’s stock valued at $473,000 after buying an additional 107 shares during the period. HighTower Advisors LLC raised its position in Syneos Health by 1.1% during the 4th quarter. HighTower Advisors LLC now owns 11,206 shares of the company’s stock worth $1,148,000 after buying an additional 119 shares during the last quarter. Advisor Group Holdings Inc. raised its position in Syneos Health by 0.5% during the 4th quarter. Advisor Group Holdings Inc. now owns 27,972 shares of the company’s stock worth $2,871,000 after buying an additional 133 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in shares of Syneos Health by 59.6% in the 4th quarter. First Horizon Advisors Inc. now owns 391 shares of the company’s stock worth $39,000 after acquiring an additional 146 shares during the period. Institutional investors own 98.38% of the company’s stock.
About Syneos Health (Get Rating)
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.